<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methylergonovine (methylergometrine): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methylergonovine (methylergometrine): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Methylergonovine (methylergometrine): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10860" href="/d/html/10860.html" rel="external">see "Methylergonovine (methylergometrine): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45279977"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Methergine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F195242"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Ergot Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F195228"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62aeceee-be44-43a2-be54-aea16c93cda5">Postpartum hemorrhage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postpartum hemorrhage:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 0.2 mg 3 to 4 times daily in the puerperium for up to 7 days (maximum duration: 1 week).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> 0.2 mg after delivery of anterior shoulder, after delivery of placenta, or during puerperium; may be repeated every 2 to 4 hours as needed. <b>Note:</b> IV administration should only be considered during life-threatening situations.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990306"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987626"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F195193"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension, hypotension, palpitations, tachycardia, thrombophlebitis, vasoconstriction, vasospasm</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Water intoxication</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, nausea, unpleasant taste, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, hallucination, headache, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lower limb cramp</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, nasal congestion</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Tsui 2001), angina pectoris, atrioventricular block, bradycardia (Ibrahim 2008), chest pain (Ibrahim 2008), coronary artery vasospasm (Jang 2023), ventricular fibrillation, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident, paresthesia</p></div>
<div class="block coi drugH1Div" id="F195205"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to methylergonovine or any component of the formulation; hypertension; preeclampsia; pregnancy</p></div>
<div class="block war drugH1Div" id="F195190"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Coronary artery disease: Patients with coronary artery disease (CAD) or risk factors for CAD may be more likely to develop myocardial ischemia and infarction following methylergonovine-induced vasospasm.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Labor: Use with caution in the second stage of labor.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sepsis: Use with caution in patients with sepsis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vascular disease: Use with caution in patients with obliterative vascular disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• IV administration: Not for routine IV administration due to risk of inducing sudden hypertensive and cerebrovascular accidents. IV administration should only be considered during life-threatening situations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Medication errors: Inadvertent administration to newborns has been reported.</p></div>
<div class="block foc drugH1Div" id="F195200"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as maleate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.2 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as maleate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.2 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as maleate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Methergine: 0.2 mg [contains methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.2 mg</p></div>
<div class="block geq drugH1Div" id="F195186"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F195207"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Methylergonovine Maleate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2 mg/mL (per mL): $8.80 - $35.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Methergine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2 mg (per each): $74.70</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Methylergonovine Maleate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2 mg (per each): $67.23 - $70.97</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F195202"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. Do not routinely administer IV because of the possibility of inducing sudden hypertension and cerebrovascular accident; only consider IV administration during life-threatening situations.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: May be administered intramuscularly.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Available in tablets for oral administration.</p></div>
<div class="block hazard drugH1Div" id="F49132860"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. For injection preparation, NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs). Double gloving, a gown, and (if dosage form allows) CSTDs are required during injection administration (NIOSH 2016).  </p></div>
<div class="block use drugH1Div" id="F195201"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Postpartum hemorrhage: </b>Management of uterine atony, hemorrhage and subinvolution of the uterus following delivery of the placenta; control of uterine hemorrhage following delivery of the anterior shoulder in the second stage of labor.</p></div>
<div class="block mst drugH1Div" id="F195251"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Methergine may be confused with Brethine</p>
<p style="text-indent:-2em;margin-left:4em;">Methylergonovine and terbutaline parenteral dosage forms look similar. Due to their contrasting indications, use care when administering these agents.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Inadvertent administration of methylergonovine to newborns has been reported in place of routine medications (eg, vitamin K or hepatitis B vaccine); store methylergonovine injection separately from medications used for neonates.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F195238"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F195195"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates) may enhance the vasoconstricting effect of Alpha-/Beta-Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates) may enhance the vasoconstricting effect of Alpha1-Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: Ergot Derivatives may enhance the adverse/toxic effect of Bromocriptine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypertensive effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Methylergonovine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dihydroergotamine: Ergot Derivatives may enhance the vasoconstricting effect of Dihydroergotamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the adverse/toxic effect of Ergot Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin (Withdrawn From US Market) may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methysergide: Ergot Derivatives may enhance the vasoconstricting effect of Methysergide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May enhance the serotonergic effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates) may diminish the vasodilatory effect of Nitroglycerin. Nitroglycerin may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).  Management: Avoid the use of ergot derivatives in patients receiving nitroglycerin for angina (or in any angina patient) if possible. If combined, monitor for decreased effects of nitroglycerin and increased adverse effects of the ergot derivative (eg, ergotism).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the adverse/toxic effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: May enhance the hypertensive effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxithromycin: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Ergot Derivatives may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F195208"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Methylergonovine is intended for use after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium; use is contraindicated during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Methylergonovine is used for the treatment of postpartum hemorrhage due to uterine atony. Methylergonovine is recommended when a supplemental uterotonic agent is needed; due to maternal side effects it is not preferred for initial use (ACOG 183 2017).</p></div>
<div class="block brc drugH1Div" id="F4803896"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Methylergonovine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of methylergonovine in breast milk are available from multiple studies (Erkkola 1978; Iwamura 1981; Nakamichi 2012; Vogel 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">• Methylergonovine 0.125 mg was administered orally 3 times daily for 5 days to 8 women treated for incomplete postpartum involution. Milk concentrations were evaluated 1 and 8 hours after the morning dose on day 5. The highest milk concentrations were observed 1 hour after the dose and ranged from &lt;0.5 ng/mL (lower limit of detection) to 1.3 ng/mL (Erkkola 1978). Using data from this study and a milk concentration of 1.3 ng/mL, the estimated daily infant dose via breast milk is 195 ng/kg/day and the relative infant dose (RID) of methylergonovine is 3.9% compared to the weight-adjusted maternal. Higher doses are recommended in current product labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Adverse events may be observed in breastfed infants and may include agitation, diarrhea, increased blood pressure, bradycardia, seizures, tachycardia, or vomiting (Methylergometrine 2014). Prolactin concentrations (and possibly milk supply) may be changed following methylergonovine administration; this may be dependent upon dose and route of administration (Del Pozo 1975; Weiss 1975).</p>
<p style="text-indent:-2em;margin-left:2em;">Some manufacturers do not recommend breastfeeding during therapy or for 12 hours after the last dose due to adverse reactions reported in breastfeeding infants. However, other sources note use may be acceptable if breastfeeding (Ito 2000).</p></div>
<div class="block mop drugH1Div" id="F15255056"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure</p></div>
<div class="block pha drugH1Div" id="F195189"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Increases the tone, rate and amplitude of contractions on the smooth muscles of the uterus, producing sustained contractions which shortens the third stage of labor and reduces blood loss. </p></div>
<div class="block phk drugH1Div" id="F195204"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Oxytocic: Oral: 5-10 minutes; IM: 2-5 minutes; IV: Immediately </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Oral: ~3 hours; IM: ~3 hours; IV: 45 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 39-73 L </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Oral: 60%; IM: 78% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~3 hours (range: 1.5-12.7 hours) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Oral: 0.3-2 hours; IM: 0.2-0.6 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine and feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F195209"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Basofortina</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Methergin | Metherspan</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Lerin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Methergin | Methylergobrevin | Methylergometrin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ergometrin | Methergin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Lerin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Methergina</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Methergin | Myomergin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Demergin | Ergovit | Methergine | Mitrotan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Methergin | Metherinal | Methovin | Methyl ergometrine | Methylergometrine | Metiagin | Metilat | Metvell | Myotonic | Pospargin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Algometrine | Ergagin | Ergogin | Ergolin | Ergoriv | Gotrin | Hicon | Ingagen-m | Lerin | Limitex | Mem | Memcad | Memjet | Mergox | Merzen | Metergo | Metermin | Metharmed | Methastar | Methergin | Methygin | Methylergometrine | Utergin | Wergomet</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Derganin | Derganin taiyo | Levospan | Metenarin | Methecrine | Methergin | Methylegyl kayaku | Partan m | Ryegonovin | Takimetrin m | Uruteon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ergospar m | Methergin | Unidergin | Unidergine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Methergine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Methergin | Methylergometrin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Methergin | Neometrin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ergojen | Ergon | Ergotec | Mergot | Methergin | Mexytrine | Usa-methylergometrine maleate | Usamema | Utergin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ergomin | Methergin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Methergine | Methylergonovine maleate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Methergin | Metilergometrina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Basofortina | Femitranol</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ermetrin | Gynogin | Methergin | Methylergometrine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ergotyl</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Methergin | Metiler | Uterjin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Methergin | Methylergonovine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Methylergometrin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Ergomin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Methergin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Ergogin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28937571">
<a name="28937571"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins - Obstetrics. Practice bulletin no. 183: postpartum hemorrhage. <i>Obstet Gynecol</i>. 2017;130(4):e168-e186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/28937571/pubmed" id="28937571" target="_blank">28937571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17687059">
<a name="17687059"></a>Cohen V, Jellinek SP, Teperikidis L, et al, “Room-Temperature Storage of Medications Labeled for Refrigeration,” <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/17687059/pubmed" id="17687059" target="_blank">17687059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9806101">
<a name="9806101"></a>de Groot AN, van Dongen PW, Vree TB, et al, “Ergot Alkaloids. Current Status and Review of Clinical Pharmacology and Therapeutic Use Compared With Other Oxytocics in Obstetrics and Gynaecology,” <i>Drugs</i>, 1998, 56(4):523-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/9806101/pubmed" id="9806101" target="_blank">9806101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1200082">
<a name="1200082"></a>Del Pozo E, Brun Del Re R, Hinselmann M. Lack of effect of methyl-ergonovine on postpartum lactation. <i>Am J Obstet Gynecol</i>. 1975;123(8):845-846.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/1200082/pubmed" id="1200082" target="_blank">1200082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-730424">
<a name="730424"></a>Erkkola R, Kanto J, Allonen H, Kleimola T, Mäntylä R. Excretion of methylergometrine (methylergonovine) into the human breast milk. <i>Int J Clin Pharmacol Biopharm</i>. 1978;16(12):579-580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/730424/pubmed" id="730424" target="_blank">730424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18831911">
<a name="18831911"></a>Ibrahim SM, Mustafa E, Louon A. Postpartum severe sinus bradycardia following methylergonovine administration. <i>J Int Med Res</i>. 2008;36(5):1129-1133. doi:10.1177/147323000803600534<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/18831911/pubmed" id="18831911" target="_blank">18831911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7264872">
<a name="7264872"></a>Iwamura S, Kambegawa A. Determination of methylergometrine and dihydroergotoxine in biological fluids. <i>J Pharmacobiodyn</i>. 1981;4(4):275-281. doi:10.1248/bpb1978.4.275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/7264872/pubmed" id="7264872" target="_blank">7264872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37069508">
<a name="37069508"></a>Jang SK, Berlacher K, Hauspurg A. Post-partum myocardial ischemia due to intramuscular methylergonovine-induced coronary vasospasm: case report. <i>BMC Cardiovasc Disord</i>. 2023;23(1):199. doi:10.1186/s12872-023-03216-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/37069508/pubmed" id="37069508" target="_blank">37069508</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Methergine (methylergonovine maleate) [prescribing information]. Baltimore, MD: Lupin Pharma; January 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24860899">
<a name="24860899"></a>Methylergometrine: adverse effects in breastfed infants. <i>Prescrire Int</i>. 2014;23(148):102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/24860899/pubmed" id="24860899" target="_blank">24860899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Methylergonovine.2019.10">
<a name="Methylergonovine.2019.10"></a>Methylergonovine maleate [prescribing information]. Berlin, CT: Breckenridge Pharmaceutical, Inc; October 2019.</div>
</li>
<li>
<div class="reference">
                  Nakamichi T, Yawata A, Hojo H, Kagaya H, Kobayashi S, Chikuma T. Monitoring of methylergometrine in human breast milk by solid-phase extraction and high-performance liquid chromatography with fluorimetric detection. <i>Pharmazie</i>. 2012;67(6):482-484.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11176106">
<a name="11176106"></a>Tsui BC, Stewart B, Fitzmaurice A, Williams R. Cardiac arrest and myocardial infarction induced by postpartum intravenous ergonovine administration. <i>Anesthesiology</i>. 2001;94(2):363-364. doi:10.1097/00000542-200102000-00033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/11176106/pubmed" id="11176106" target="_blank">11176106</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15592308">
<a name="15592308"></a>Vogel D, Burkhardt T, Rentsch K, et al, "Misoprostol versus Methylergometrine: Pharmacokinetics in Human Milk," <i>Am J Obstet Gynecol</i>, 2004, 191(6):2168-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/15592308/pubmed" id="15592308" target="_blank">15592308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1080266">
<a name="1080266"></a>Weiss G, Klein S, Shenkman L, Kataoka K, Hollander CS. Effect of methylergonovine on puerperal prolactin secretion. <i>Obstet Gynecol</i>. 1975;46(2):209-210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylergonovine-methylergometrine-drug-information/abstract-text/1080266/pubmed" id="1080266" target="_blank">1080266</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9637 Version 303.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
